• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by 111, Inc. (Amendment)

    5/27/21 5:00:44 PM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $YI alert in real time by email
    SC 13G/A 1 tm2115562d1_sc13ga.htm SCHEDULE 13G/A Proof - Test Table.htm

     

     

     

      UNITED STATES  
      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
         

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    111, Inc.

    (Name of Issuer)

     

    Common Stock, par value of $0.00005 per share

    (Title of Class of Securities)

     

    68247Q102**

    (CUSIP Number)

     

    March 2, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ¨ Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    x Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    ** This CUSIP applies to the American Depositary Shares, each representing two Class A ordinary shares (“ADS”). No CUSIP has

    been assigned to the Class A ordinary shares.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 68247Q102

     

      1.

    Names of Reporting Persons
    I.R.S. Identification Nos. of Above Persons (Entities Only)

    Verlinvest Asia (HK) Limted

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x
        (b) ¨
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Hong Kong

     

      5. Sole Voting Power
    0
     
    6. Shared Voting Power
    7,618,966
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    7,618,966
     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    7,618,966
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11. Percent of Class Represented by Amount in Row (9)
    4.61%(1)
     
      12. Type of Reporting Person (See Instructions)
    CO

     


    (1) Based on the number of shares outstanding of 165,353,402 Class A ordinary shares outstanding on an as-converted basis as of Dcember 31, 2020, as stated in the Issuer's Form 20-K filed with the SEC on April 30, 2021.

     

    2

     

     

    CUSIP No. 68247Q102

     

      1.

    Names of Reporting Persons
    I.R.S. Identification Nos. of Above Persons (Entities Only)

    Verlinvest Asia Pte Ltd

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x
        (b) ¨
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Singapore

     

      5. Sole Voting Power
    0
     
    6. Shared Voting Power
    7,618,966
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    7,618,966
     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    7,618,966
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11. Percent of Class Represented by Amount in Row (9)
    4.61%(1)
     
      12. Type of Reporting Person (See Instructions)
    CO

     


    (1) Based on the number of shares outstanding of 165,353,402 Class A ordinary shares outstanding on an as-converted basis as of Dcember 31, 2020, as stated in the Issuer's Form 20-K filed with the SEC on April 30, 2021.

     

    3

     

     

    CUSIP No. 68247Q102

     

      1.

    Names of Reporting Persons
    I.R.S. Identification Nos. of Above Persons (Entities Only)

    Verlinvest SA

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x
        (b) ¨
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Belgium

     

      5. Sole Voting Power
    0
     
    6. Shared Voting Power
    7,618,966
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    7,618,966

     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    7,618,966
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11. Percent of Class Represented by Amount in Row (9)
    4.61%(1)
     
      12. Type of Reporting Person (See Instructions)
    CO

     

    (1) Based on the number of shares outstanding of 165,353,402 Class A ordinary shares outstanding on an as-converted basis as of Dcember 31, 2020, as stated in the Issuer's Form 20-K filed with the SEC on April 30, 2021.

     

    4

     

     

    CUSIP No. 68247Q102

     

      1.

    Names of Reporting Persons
    I.R.S. Identification Nos. of Above Persons (Entities Only)

    Verlinvest Group SA

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x
        (b) ¨
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Belgium

     

      5. Sole Voting Power
    0
     
    6. Shared Voting Power
    7,618,966
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    7,618,966

     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    7,618,966
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11. Percent of Class Represented by Amount in Row (9)
    4.61%(1)
     
      12. Type of Reporting Person (See Instructions)
    CO

     

    (1) Based on the number of shares outstanding of 165,353,402 Class A ordinary shares outstanding on an as-converted basis as of Dcember 31, 2020, as stated in the Issuer's Form 20-K filed with the SEC on April 30, 2021.

     

    5

     

     

    CUSIP No. 68247Q102

     

      1.

    Names of Reporting Persons
    I.R.S. Identification Nos. of Above Persons (Entities Only)

    Vedihold SA

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) x
        (b) ¨
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Luxembourg

     

      5. Sole Voting Power
    0
     
    6. Shared Voting Power
    7,618,966
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    7,618,966

     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    7,618,966
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11. Percent of Class Represented by Amount in Row (9)
    4.61%(1)
     
      12. Type of Reporting Person (See Instructions)
    CO

     

    (1) Based on the number of shares outstanding of 165,353,402 Class A ordinary shares outstanding on an as-converted basis as of Dcember 31, 2020, as stated in the Issuer's Form 20-K filed with the SEC on April 30, 2021.

     

    6

     

     

    Item 1.
      (a) Name of Issuer
    111, Inc.
      (b) Address of Issuer’s Principal Executive Offices
    3-5F, No. 295 ZuChongZhi Road, Pudong New Area, Shanghai, the People’s Republic of China
     
    Item 2.
      (a)

    Name of Person Filing
    This Schedule 13G/A is being filed jointly on behalf of the following reporting persons: (i) Verlinvest Asia (HK) Limited, a limited company incorporated in Hong Kong, (ii) Verlinvest SA, a company incorporated in Belgium, (iii) Verlinvest Group SA, a company incorporated in Belgium, and (iv) Vedihold SA, a company incorporated in Luxembourg (together, the “Reporting Persons”).

     

    The Reporting Persons have entered into a joint filing agreement filed as Exhibit 99.1 to the Schedule 13G filed January 18, 2019, pursuant to which the Reporting Persons have agreed to file this statement jointly in acordance with the provisions of Rule 13-d(k)(1) under the Exchange Act of 1934, as amended.

      (b) Address of the Principal Office or, if none, Residence
    31/F., 148 Electric Road, North Point, Hong Kong.
      (c) Citizenship
    See cover pages for each of the Reporting Persons.
      (d) Title of Class of Securities
    Class A ordinary shares, par value of $0.00005 per share.
      (e) CUSIP Number
    There is no CUSIP number assigned to the Class A ordinary shares. CUSIP number 68247Q102 has been assigned to the ADSs of the Issuer, which are quoted on The NASDAQ Global Select Market under the symbol “YI.” Each ADS represents 2 Class A ordinary shares.
     
    Item 3.  
    Not applicable.

     

    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount beneficially owned:    
      (b) Percent of class:    
      (c) Number of shares as to which the person has:
        (i) Sole power to vote or to direct the vote    
        (ii) Shared power to vote or to direct the vote     
        (iii) Sole power to dispose or to direct the disposition of    
        (iv) Shared power to dispose or to direct the disposition of    
       

    See the cover pages for each of the Reporting Persons.

     

    7

     

     

    Item 5. Ownership of Five Percent or Less of a Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   x.
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Not applicable.
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.
    The Reporting Persons named herein are making this single, joint filing because they may be deemed to constitute a “group” within the meaning of Section 13(d)(3) of the Exchange Act. A joint filing agreement among the Reporting Persons was attached as Exhibit 99.1 to the Schedule 13G, filed January 18, 2019.
     
    Item 9. Notice of Dissolution of Group.
    Not applicable.

     

    8

     

     

    Item 10. Certification.
    Not applicable.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

        May 27, 2021
        Date
         
      Verlinvest Asia (HK) Limited  
         
      /s/ Raphael Thiolon /s/ Axelle Henry
      Name: Raphael Thiolon Name: Axelle Henry
      Title:Director Title:Director
         
      Verlinvest Asia Pte Ltd  
         
      /s/ Raphael Thiolon /s/ Axelle Henry
      Name: Raphael Thiolon Name: Axelle Henry
      Title: Director Title: Director
         
      Verlinvest SA  
         
      /s/ Raphael Hulpiau /s/ Axelle Henry
      Name: Raphael Hulpiau Name: Axelle Henry
      Title: Joint Proxy-holder Title: Joint Proxy-holder
         
      Verlinvest Group SA  
         
      /s/ Raphael Hulpiau /s/ Axelle Henry
      Name: Raphael Hulpiau Name: Axelle Henry
      Title: Joint Proxy-holder Title: Joint Proxy-holder
         
      Vedihold SA  
         
      /s/ Fons Mangen  
      Name: Fons Mangen  
      Title: Managing Director  

     

    9

     

     

    Exhibit Index

     

    Exhibit 99.1: Joint Filing Agreement, dated May 27, 2021, by and among the Reporting Persons.

     

    10

     

    Get the next $YI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $YI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $YI
    SEC Filings

    View All

    SEC Form 6-K filed by 111 Inc.

    6-K - 111, Inc. (0001738906) (Filer)

    12/17/25 6:13:16 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 6-K filed by 111 Inc.

    6-K - 111, Inc. (0001738906) (Filer)

    9/17/25 6:09:10 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form 20-F/A filed by 111 Inc.

    20-F/A - 111, Inc. (0001738906) (Filer)

    8/29/25 6:03:53 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    111, Inc. Announces Third Quarter 2025 Unaudited Financial Results

    Transition from An Asset-Heavy Business Model to An Asset-Light Business ModelAchieved Quarterly Non-GAAP Net ProfitabilityMaintained Non-GAAP Operational Profitability for Three Consecutive QuartersAchieved Quarterly Positive Operating Cash FlowSHANGHAI, Dec. 17, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Total operating expenses were RMB180.3 million (US$25.3 million)

    12/17/25 1:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111, Inc. Announces Second Quarter 2025 Unaudited Financial Results

    Maintained Quarterly Operational ProfitabilityOperating Expenses as a Percentage of Revenues Decreased 20 Basis Points YoYMaintained Positive Operating Cash Flow in the First Half of the YearSHANGHAI, Sept. 17, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Total operating expenses were RMB185.3 million (US$25.9 million), an improvement of 9.3% compared to RMB204.3 million in

    9/17/25 2:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111, Inc. Announces First Quarter 2025 Unaudited Financial Results

    Maintained Quarterly Operational ProfitabilityOperating Expenses as a Percentage of Revenues Decreased 30 Basis Points YoYMaintained Quarterly Positive Operating Cash FlowSHANGHAI, June 19, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Net revenues were RMB3.5 billion (US$486.3 million), remaining relatively flat compared to the same quarter last year.Total operating expenses

    6/19/25 3:03:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup resumed coverage on 111, Inc. with a new price target

    Citigroup resumed coverage of 111, Inc. with a rating of Buy and set a new price target of $16.00

    4/15/21 6:56:01 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Financials

    Live finance-specific insights

    View All

    111, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results

    Achieved First-Ever Annual Operating ProfitBottom Line Improved by RMB332.7 Million YoY in 2024Operating Expenses as a Percentage of Revenues Decreased 230 Basis Points YoY in 2024 Q4'24 Operating Expenses as a Percentage of Revenues Decreased 470 Basis Points YoYAchieved First-Ever Annual Positive Operating Cash FlowSHANGHAI, March 20, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024. Four

    3/20/25 1:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111 to Announce Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results on March 20, 2025 - Conference Call to Follow

    SHANGHAI, Feb. 20, 2025 /PRNewswire/ -- 111, Inc. (NASDAQ:YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year 2024 ended December 31, 2024, before the U.S. market opens on Thursday, March 20, 2025. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, March 20, 2025 (7:30 PM Beijing Time on the same day). Details for the conference call are as follows: Conference Topic: 111, Inc. Fourth Q

    2/20/25 5:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111, Inc. Announces Third Quarter 2024 Unaudited Financial Results

    Maintained Operational Profitability for the Third Consecutive QuarterOperating Expenses as a Percentage of Revenues Decreased 160 Basis Points YoYHeld Positive Operating Cash Flow for Three Consecutive QuartersSHANGHAI, Nov. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Net revenues were RMB3.6 billion (US$513.1 million), remaining relatively flat compared to the same

    11/27/24 1:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Leadership Updates

    Live Leadership Updates

    View All

    111, Inc. Announces Change to Board of Directors

    SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that Dr. Leon Lian Yong Chen has tendered his resignation from the position as the Company's director for personal reasons, effective on November 4, 2024. The board has also appointed Mr. Yang "Luke" Chen, currently serving as the Company's Senior Finance Executive, as a new director, effective November 4, 2024. Dr. Lian Yong Chen has served on the board of directors of the Company since May 2019. "I am grateful to Dr

    11/4/24 5:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111 Announces Appointment of New Auditor

    SHANGHAI, July 19, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced  the appointment of  Grant Thornton Zhitong Certified Public Accountants LLP ("Grant Thornton") as the Company's independent registered public accounting firm, effective July 19, 2024, replacing Deloitte Touche Tohmatsu Certified Public Accountants LLP. The change of the Company's independent registered public accounting firm was made after a careful and thorough evaluation process and has been approved by 111's boar

    7/19/24 8:45:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee

    SHANGHAI, Sept. 23, 2022 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), consisting of three independent directors, Mr. Jian Sun, who is the chairman of the Special Committee, Mr. Nee Chuan Teo and Mr. Jun Luo, established by the Company's Board of Directors (the "Board") has retained Houlihan Lokey China Limited as its independent financial advisor and Kirkland & Ellis as its U.S. legal counsel in connection with its review and evaluation of the previously announced preliminary non-binding proposal letter dated September 9, 2022 (the "Proposal")

    9/23/22 12:30:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by 111 Inc. (Amendment)

    SC 13D/A - 111, Inc. (0001738906) (Subject)

    2/27/24 8:02:40 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13D/A filed by 111 Inc. (Amendment)

    SC 13D/A - 111, Inc. (0001738906) (Subject)

    7/17/23 9:00:05 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13D/A filed by 111 Inc. (Amendment)

    SC 13D/A - 111, Inc. (0001738906) (Subject)

    10/31/22 7:57:04 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples